Cargando…
Case Report: A Rare Case of Metachronous Multiple Primary Lung Cancers in a Patient With Successful Management by Switching From Anti-PD-1 Therapy to Anti-PD-L1 Therapy
Without global standard diagnostic criteria, distinguishing multiple primary lung cancers (MPLCs) from intrapulmonary metastasis or histologic transformation has been a big challenge in clinical practice. Here, we described a rare case of metachronous adenocarcinoma and small cell lung cancer (SCLC)...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8207139/ https://www.ncbi.nlm.nih.gov/pubmed/34149722 http://dx.doi.org/10.3389/fimmu.2021.683202 |
_version_ | 1783708712694710272 |
---|---|
author | Lin, Xinqing Qiu, Guihuan Li, Fang Deng, Haiyi Qin, Yinyin Xie, Xiaohong Jiang, Juhong Song, Yong Liu, Ming Zhou, Chengzhi |
author_facet | Lin, Xinqing Qiu, Guihuan Li, Fang Deng, Haiyi Qin, Yinyin Xie, Xiaohong Jiang, Juhong Song, Yong Liu, Ming Zhou, Chengzhi |
author_sort | Lin, Xinqing |
collection | PubMed |
description | Without global standard diagnostic criteria, distinguishing multiple primary lung cancers (MPLCs) from intrapulmonary metastasis or histologic transformation has been a big challenge in clinical practice. Here, we described a rare case of metachronous adenocarcinoma and small cell lung cancer (SCLC) in a patient who developed drug resistance to pembrolizumab. Both DNA-sequencing and RNA-sequencing were performed on primary adenocarcinoma and resistant lesions. Through the comparison of primary adenocarcinoma and novel lesion mutation profiles, along with bioinformatic estimation of immune proportion by using RNA sequence data, we revealed the origin and tumor microenvironment of the two lesions. No shared mutations were detected between lung adenocarcinoma (LUAD) and SCLC from the same patient, suggesting these two lesions might be from separate primary lung cancers. Compared to LUAD, SCLC showed a relatively cold microenvironment, including negative PD-L1. The patient obtained durable clinical benefits upon treatment with atezolizumab, without experiencing immune-related adverse events. Disease progression should be monitored with prompt re-biopsy and molecular profiling to spot a potential histologic change and to shed light on therapeutic alternatives. The use of atezolizumab, either alone or in combination with other agents, may be a potential therapeutic strategy for patients with both LUAD and SCLC. |
format | Online Article Text |
id | pubmed-8207139 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-82071392021-06-17 Case Report: A Rare Case of Metachronous Multiple Primary Lung Cancers in a Patient With Successful Management by Switching From Anti-PD-1 Therapy to Anti-PD-L1 Therapy Lin, Xinqing Qiu, Guihuan Li, Fang Deng, Haiyi Qin, Yinyin Xie, Xiaohong Jiang, Juhong Song, Yong Liu, Ming Zhou, Chengzhi Front Immunol Immunology Without global standard diagnostic criteria, distinguishing multiple primary lung cancers (MPLCs) from intrapulmonary metastasis or histologic transformation has been a big challenge in clinical practice. Here, we described a rare case of metachronous adenocarcinoma and small cell lung cancer (SCLC) in a patient who developed drug resistance to pembrolizumab. Both DNA-sequencing and RNA-sequencing were performed on primary adenocarcinoma and resistant lesions. Through the comparison of primary adenocarcinoma and novel lesion mutation profiles, along with bioinformatic estimation of immune proportion by using RNA sequence data, we revealed the origin and tumor microenvironment of the two lesions. No shared mutations were detected between lung adenocarcinoma (LUAD) and SCLC from the same patient, suggesting these two lesions might be from separate primary lung cancers. Compared to LUAD, SCLC showed a relatively cold microenvironment, including negative PD-L1. The patient obtained durable clinical benefits upon treatment with atezolizumab, without experiencing immune-related adverse events. Disease progression should be monitored with prompt re-biopsy and molecular profiling to spot a potential histologic change and to shed light on therapeutic alternatives. The use of atezolizumab, either alone or in combination with other agents, may be a potential therapeutic strategy for patients with both LUAD and SCLC. Frontiers Media S.A. 2021-06-02 /pmc/articles/PMC8207139/ /pubmed/34149722 http://dx.doi.org/10.3389/fimmu.2021.683202 Text en Copyright © 2021 Lin, Qiu, Li, Deng, Qin, Xie, Jiang, Song, Liu and Zhou https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Lin, Xinqing Qiu, Guihuan Li, Fang Deng, Haiyi Qin, Yinyin Xie, Xiaohong Jiang, Juhong Song, Yong Liu, Ming Zhou, Chengzhi Case Report: A Rare Case of Metachronous Multiple Primary Lung Cancers in a Patient With Successful Management by Switching From Anti-PD-1 Therapy to Anti-PD-L1 Therapy |
title | Case Report: A Rare Case of Metachronous Multiple Primary Lung Cancers in a Patient With Successful Management by Switching From Anti-PD-1 Therapy to Anti-PD-L1 Therapy |
title_full | Case Report: A Rare Case of Metachronous Multiple Primary Lung Cancers in a Patient With Successful Management by Switching From Anti-PD-1 Therapy to Anti-PD-L1 Therapy |
title_fullStr | Case Report: A Rare Case of Metachronous Multiple Primary Lung Cancers in a Patient With Successful Management by Switching From Anti-PD-1 Therapy to Anti-PD-L1 Therapy |
title_full_unstemmed | Case Report: A Rare Case of Metachronous Multiple Primary Lung Cancers in a Patient With Successful Management by Switching From Anti-PD-1 Therapy to Anti-PD-L1 Therapy |
title_short | Case Report: A Rare Case of Metachronous Multiple Primary Lung Cancers in a Patient With Successful Management by Switching From Anti-PD-1 Therapy to Anti-PD-L1 Therapy |
title_sort | case report: a rare case of metachronous multiple primary lung cancers in a patient with successful management by switching from anti-pd-1 therapy to anti-pd-l1 therapy |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8207139/ https://www.ncbi.nlm.nih.gov/pubmed/34149722 http://dx.doi.org/10.3389/fimmu.2021.683202 |
work_keys_str_mv | AT linxinqing casereportararecaseofmetachronousmultipleprimarylungcancersinapatientwithsuccessfulmanagementbyswitchingfromantipd1therapytoantipdl1therapy AT qiuguihuan casereportararecaseofmetachronousmultipleprimarylungcancersinapatientwithsuccessfulmanagementbyswitchingfromantipd1therapytoantipdl1therapy AT lifang casereportararecaseofmetachronousmultipleprimarylungcancersinapatientwithsuccessfulmanagementbyswitchingfromantipd1therapytoantipdl1therapy AT denghaiyi casereportararecaseofmetachronousmultipleprimarylungcancersinapatientwithsuccessfulmanagementbyswitchingfromantipd1therapytoantipdl1therapy AT qinyinyin casereportararecaseofmetachronousmultipleprimarylungcancersinapatientwithsuccessfulmanagementbyswitchingfromantipd1therapytoantipdl1therapy AT xiexiaohong casereportararecaseofmetachronousmultipleprimarylungcancersinapatientwithsuccessfulmanagementbyswitchingfromantipd1therapytoantipdl1therapy AT jiangjuhong casereportararecaseofmetachronousmultipleprimarylungcancersinapatientwithsuccessfulmanagementbyswitchingfromantipd1therapytoantipdl1therapy AT songyong casereportararecaseofmetachronousmultipleprimarylungcancersinapatientwithsuccessfulmanagementbyswitchingfromantipd1therapytoantipdl1therapy AT liuming casereportararecaseofmetachronousmultipleprimarylungcancersinapatientwithsuccessfulmanagementbyswitchingfromantipd1therapytoantipdl1therapy AT zhouchengzhi casereportararecaseofmetachronousmultipleprimarylungcancersinapatientwithsuccessfulmanagementbyswitchingfromantipd1therapytoantipdl1therapy |